242 related articles for article (PubMed ID: 30530501)
1. Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
Barazas M; Gasparini A; Huang Y; Küçükosmanoğlu A; Annunziato S; Bouwman P; Sol W; Kersbergen A; Proost N; de Korte-Grimmerink R; van de Ven M; Jonkers J; Borst GR; Rottenberg S
Cancer Res; 2019 Feb; 79(3):452-460. PubMed ID: 30530501
[TBL] [Abstract][Full Text] [Related]
2. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
4. DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.
Gupta R; Somyajit K; Narita T; Maskey E; Stanlie A; Kremer M; Typas D; Lammers M; Mailand N; Nussenzweig A; Lukas J; Choudhary C
Cell; 2018 May; 173(4):972-988.e23. PubMed ID: 29656893
[TBL] [Abstract][Full Text] [Related]
5. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
[TBL] [Abstract][Full Text] [Related]
6. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Xu G; Chapman JR; Brandsma I; Yuan J; Mistrik M; Bouwman P; Bartkova J; Gogola E; Warmerdam D; Barazas M; Jaspers JE; Watanabe K; Pieterse M; Kersbergen A; Sol W; Celie PHN; Schouten PC; van den Broek B; Salman A; Nieuwland M; de Rink I; de Ronde J; Jalink K; Boulton SJ; Chen J; van Gent DC; Bartek J; Jonkers J; Borst P; Rottenberg S
Nature; 2015 May; 521(7553):541-544. PubMed ID: 25799992
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Nacson J; Krais JJ; Bernhardy AJ; Clausen E; Feng W; Wang Y; Nicolas E; Cai KQ; Tricarico R; Hua X; DiMarcantonio D; Martinez E; Zong D; Handorf EA; Bellacosa A; Testa JR; Nussenzweig A; Gupta GP; Sykes SM; Johnson N
Cell Rep; 2018 Sep; 24(13):3513-3527.e7. PubMed ID: 30257212
[TBL] [Abstract][Full Text] [Related]
8. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
9. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
[TBL] [Abstract][Full Text] [Related]
10. 53BP1 Enforces Distinct Pre- and Post-resection Blocks on Homologous Recombination.
Callen E; Zong D; Wu W; Wong N; Stanlie A; Ishikawa M; Pavani R; Dumitrache LC; Byrum AK; Mendez-Dorantes C; Martinez P; Canela A; Maman Y; Day A; Kruhlak MJ; Blasco MA; Stark JM; Mosammaparast N; McKinnon PJ; Nussenzweig A
Mol Cell; 2020 Jan; 77(1):26-38.e7. PubMed ID: 31653568
[TBL] [Abstract][Full Text] [Related]
11. 53BP1-shieldin-dependent DSB processing in BRCA1-deficient cells requires CST-Polα-primase fill-in synthesis.
Mirman Z; Sasi NK; King A; Chapman JR; de Lange T
Nat Cell Biol; 2022 Jan; 24(1):51-61. PubMed ID: 35027730
[TBL] [Abstract][Full Text] [Related]
12. TRIP13 regulates DNA repair pathway choice through REV7 conformational change.
Clairmont CS; Sarangi P; Ponnienselvan K; Galli LD; Csete I; Moreau L; Adelmant G; Chowdhury D; Marto JA; D'Andrea AD
Nat Cell Biol; 2020 Jan; 22(1):87-96. PubMed ID: 31915374
[TBL] [Abstract][Full Text] [Related]
13. Histone chaperone ASF1 acts with RIF1 to promote DNA end joining in BRCA1-deficient cells.
Tang M; Chen Z; Wang C; Feng X; Lee N; Huang M; Zhang H; Li S; Xiong Y; Chen J
J Biol Chem; 2022 Jun; 298(6):101979. PubMed ID: 35472331
[TBL] [Abstract][Full Text] [Related]
14. 53BP1-RIF1-shieldin counteracts DSB resection through CST- and Polα-dependent fill-in.
Mirman Z; Lottersberger F; Takai H; Kibe T; Gong Y; Takai K; Bianchi A; Zimmermann M; Durocher D; de Lange T
Nature; 2018 Aug; 560(7716):112-116. PubMed ID: 30022158
[TBL] [Abstract][Full Text] [Related]
15. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
[TBL] [Abstract][Full Text] [Related]
16. FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells.
Tomida J; Takata KI; Bhetawal S; Person MD; Chao HP; Tang DG; Wood RD
EMBO J; 2018 Jun; 37(12):. PubMed ID: 29789392
[TBL] [Abstract][Full Text] [Related]
17. The p53-binding protein 1-Tudor-interacting repair regulator complex participates in the DNA damage response.
Zhang A; Peng B; Huang P; Chen J; Gong Z
J Biol Chem; 2017 Apr; 292(16):6461-6467. PubMed ID: 28213517
[TBL] [Abstract][Full Text] [Related]
18. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
Aly A; Ganesan S
J Mol Cell Biol; 2011 Feb; 3(1):66-74. PubMed ID: 21278454
[TBL] [Abstract][Full Text] [Related]
19. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
20. CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance.
Fujita H; Ikeda M; Ui A; Ouchi Y; Mikami Y; Kanno SI; Yasui A; Tanaka K
Oncogene; 2022 May; 41(19):2706-2718. PubMed ID: 35393543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
